SUPN · Supernus Pharmaceuticals Inc
United States · RS rating 22 · As of 2026-11-03
| Price | 28.15 USD |
|---|---|
| 1-day change | -22.4% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 20 / 23 / 47 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 18 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +91.2% |
| Sales growth Q/Q | +10.1% |
| Distance from 52-week high | +32.7% |
| Market cap (USD) | $2.9B |